Pfizer

Oncology Research and Development Postdoctoral Program

Kim Arndt, Ph.D.
Vice President

Education

Undergraduate: Albright College
Graduate: Ph.D. Biochemistry, University of Pennsylvania
Postdoctoral Training: University of Pennsylvania, Whitehead Institute/MIT

Research Interests:

The identification of new Oncology targets for small molecule inhibitors and antibody drug conjugate development.  Determination of  how the new targets contribute to cancer.

Selected Publications

Hebbard L, Cecena G, Golas J, et. al. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene, 30, 301-12 (2011).

Boschelli F, Golas JM, Petersen R, et al. A cell-based screen for inhibitors of protein folding and degradation. Cell Stress and Chaperones, 15, 913-927 (2010).

Chen Z, Venkatesan AM, Dehnhardt CM, et al. 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. Bioorg Med Chem Lett, 19, 4980-4983 (2009).